We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01454687
First Posted: October 19, 2011
Last Update Posted: April 11, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Alfred Lane, Stanford University
  Purpose
The term epidermolysis bullosa (EB) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "Revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. Some EB patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. In the revertant areas, the proteins function normally, like non-EB skin. In this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.

Condition Intervention
Epidermolysis Bullosa Procedure: Grafting of Autologous Cultured Revertant Keratinocytes

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes

Resource links provided by NLM:


Further study details as provided by Alfred Lane, Stanford University:

Primary Outcome Measures:
  • Expression of the correct protein at the basement membrane zone [ Time Frame: Week 52 ]
  • Engraftment and healing of wounds with genetically revertant keratinocytes [ Time Frame: Week 52 ]

Secondary Outcome Measures:
  • Engraftment and healing of wounds with genetically revertant keratinocytes [ Time Frame: Week 8-12 ]
  • Engraftment and healing of wounds with genetically revertant keratinocytes [ Time Frame: Week 25 ]
  • Expression of correct protein at the basement membrane zone [ Time Frame: Week 8-12 ]
  • Expression of the correct protein at the basement membrane zone [ Time Frame: Week 25 ]

Enrollment: 0
Study Start Date: October 2011
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Grafting of Autologous Cultured Revertant Keratinocytes
    Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of EB (simplex, junctional or dystrophic)
  • Areas of revertant skin that has been confirmed by biopsy
  • 18 years or older subject willing and able to give consent
  • Confirmation of EB diagnosis by immunofluorescence (IF), electron microscopy (EM), and genetic testing confirming mutation
  • At least 100 to 200 cm2 of open erosions on the trunk and/or extremities suitable for skin grafting
  • Able to undergo adequate anesthesia to allow grafting procedures to take place

Exclusion Criteria:

  • Medical instability limiting ability to travel to Stanford University Medical Center
  • The presence of medical illness expected to complicate participation and/or compromise the safety of this technique
  • Active infection with HIV, hepatitis B, or hepatitis C
  • Active infection in the area that will undergo grafting
  • Evidence of a systemic infection
  • Current evidence or a history of skin cancer in the area that will undergo grafting
  • Active drug or alcohol addiction
  • Hypersensitivity to vancomycin or amikacin
  • Receipt of chemical or biological study product for the specific treatment ofEB in the past six months
  • Positive pregnancy test or breast-feeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01454687


Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Alfred Lane, MD Stanford University
  More Information

Responsible Party: Alfred Lane, Professor, Departments of Dermatology and Pediatrics, Stanford University
ClinicalTrials.gov Identifier: NCT01454687     History of Changes
Other Study ID Numbers: IRB # 22005
First Submitted: October 13, 2011
First Posted: October 19, 2011
Last Update Posted: April 11, 2014
Last Verified: April 2014

Additional relevant MeSH terms:
Epidermolysis Bullosa
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous